Explicitly, we revealed a mechanism by which apigenin increases the availability of DR5 TRAIL receptor, while weakening the inhibitory effects of c-FLIPs and Hsp70 on the DISC, thereby overcoming the resistance of lung cancer cells to TRAIL-mediated apoptosis. The gene discussed is CFLAR; the disease is lung carcinoma.